Systematic review and meta-analysis demonstrates no significant reduction in heart failure events with ertugliflozin in cardiovascular patients, indicating uncertain clinical benefit.
Key Points
To evaluate the safety and cardiovascular efficacy of ertugliflozin on heart failure outcomes and cardiac function in patients with heart failure or high cardiovascular risk.
Searched PubMed, Scopus, Web of Science, and Cochrane Central up to December 25, 2025, for randomized controlled trials comparing ertugliflozin to placebo.
Identified 6 RCTs comprising 8,752 participants and pooled outcomes using fixed- or random-effects models based on heterogeneity.
Ertugliflozin was not associated with a significant reduction in cardiovascular mortality compared with placebo (RR 0.92, 95% CI [0.77, 1.10]; I² = 0%).
No statistically significant difference was observed for heart failure hospitalization between ertugliflozin and placebo (RR 0.49, 95% CI [0.10, 2.33]; I² = 59.9%).
Left ventricular ejection fraction showed no significant improvement with ertugliflozin (MD 1.26%, 95% CI [−0.27, 2.79]; I² = 0%), with very low certainty of evidence across outcomes.